Wall Street analysts expect Oxford Immunotec Global PLC (NASDAQ:OXFD) to report ($0.25) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Oxford Immunotec Global PLC’s earnings. The highest EPS estimate is ($0.19) and the lowest is ($0.29). Oxford Immunotec Global PLC posted earnings per share of ($0.18) in the same quarter last year, which indicates a negative year-over-year growth rate of 38.9%. The business is expected to report its next quarterly earnings report on Tuesday, November 7th.
On average, analysts expect that Oxford Immunotec Global PLC will report full year earnings of ($1.56) per share for the current financial year, with EPS estimates ranging from ($1.67) to ($1.45). For the next financial year, analysts forecast that the business will report earnings of ($0.90) per share, with EPS estimates ranging from ($1.07) to ($0.70). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Oxford Immunotec Global PLC.
Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its earnings results on Tuesday, August 1st. The company reported ($0.32) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.32). Oxford Immunotec Global PLC had a negative return on equity of 35.76% and a negative net margin of 34.58%. The firm had revenue of $26.10 million for the quarter, compared to analysts’ expectations of $25.05 million. During the same period in the previous year, the firm posted ($0.29) earnings per share. The business’s revenue was up 35.9% compared to the same quarter last year.
OXFD has been the topic of a number of research reports. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $26.00 price target on shares of Oxford Immunotec Global PLC in a research note on Thursday, August 3rd. Cowen and Company reaffirmed a “buy” rating and issued a $22.00 price target on shares of Oxford Immunotec Global PLC in a research note on Thursday, August 3rd. Zacks Investment Research lowered shares of Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Finally, BTIG Research initiated coverage on shares of Oxford Immunotec Global PLC in a research note on Thursday, September 28th. They issued a “buy” rating and a $21.00 price target on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. Oxford Immunotec Global PLC currently has an average rating of “Hold” and an average price target of $22.00.
TRADEMARK VIOLATION WARNING: This news story was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://ledgergazette.com/2017/10/09/brokerages-anticipate-oxford-immunotec-global-plc-oxfd-to-announce-0-25-eps.html.
In other Oxford Immunotec Global PLC news, COO Peter Edwardson sold 22,371 shares of the stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $17.70, for a total value of $395,966.70. Following the completion of the sale, the chief operating officer now owns 102,644 shares in the company, valued at approximately $1,816,798.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Peter Wrighton-Smith sold 55,000 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $16.78, for a total transaction of $922,900.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 90,110 shares of company stock valued at $1,523,514. 8.11% of the stock is owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in OXFD. Endurant Capital Management LP raised its holdings in Oxford Immunotec Global PLC by 3,456.1% in the 1st quarter. Endurant Capital Management LP now owns 570,971 shares of the company’s stock valued at $8,844,000 after acquiring an additional 554,915 shares during the last quarter. Redmile Group LLC raised its holdings in Oxford Immunotec Global PLC by 17.9% in the 1st quarter. Redmile Group LLC now owns 2,004,849 shares of the company’s stock valued at $31,055,000 after acquiring an additional 303,800 shares during the last quarter. Granahan Investment Management Inc. MA acquired a new stake in Oxford Immunotec Global PLC in the 1st quarter valued at about $4,577,000. Renaissance Technologies LLC raised its holdings in Oxford Immunotec Global PLC by 97.8% in the 1st quarter. Renaissance Technologies LLC now owns 363,300 shares of the company’s stock valued at $5,628,000 after acquiring an additional 179,600 shares during the last quarter. Finally, Wasatch Advisors Inc. raised its holdings in Oxford Immunotec Global PLC by 34.3% in the 2nd quarter. Wasatch Advisors Inc. now owns 423,831 shares of the company’s stock valued at $7,129,000 after acquiring an additional 108,154 shares during the last quarter. Institutional investors own 79.21% of the company’s stock.
Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) traded down 0.72% during midday trading on Wednesday, hitting $16.65. The stock had a trading volume of 56,450 shares. Oxford Immunotec Global PLC has a 52-week low of $11.88 and a 52-week high of $19.51. The firm has a 50 day moving average price of $15.83 and a 200-day moving average price of $15.64. The stock’s market cap is $384.22 million.
Oxford Immunotec Global PLC Company Profile
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.